Skip to content
DeepViews

TransMedics Group, Inc. Common Stock (TMDX) — 分析摘要

TransMedics Group, Inc. Common Stock(TMDX)的市值为3.18十亿美元,最近一年的营收同比增长了+37.1%。净利润率为31.4%。当前市盈率为21.0倍。

核心要点

  • 营收同比变化+37.1%
  • 净利润率31.4%
  • 市盈率21.0倍

与ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS板块的其他公司相比,TMDX的营收增长为+37.1%,市盈率为21.0倍。

[XNAS]

TransMedics Group, Inc. Common Stock (TMDX)

$88.43

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$3181.44M
企业价值
$2710.33M
市盈率
21.0
股息率
0.00%
EV/EBITDA
23.0
公司简介
关于
关于 TransMedics Group, Inc. Common Stock

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

行业

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

员工人数

898

总部

ANDOVER, MA

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
47
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$518.05M
总债务$20.00M
债务权益比0.04
现金及等价物$491.11M

现金流

经营现金流$145.93M
自由现金流$79.04M
自由现金流率11.82%
P/FCF 比率40.25
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。